Poster can be found in location 105.

BACKGROUND: Person-centred care (PCC) is an ethical approach, whereby a patient is regarded as an equal ‘partner’ in the design and implementation of their own care. Optimising care through PCC interventions can improve disease-specific management whilst addressing the needs of people living with long-term conditions like chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD). AIM: The aim of the study was to evaluate the cost-effectiveness of a remote PCC add-on intervention compared with usual care alone for people with CHF and / or COPD. This intervention has previously been reported to improve self-efficacy. METHODS: Patients from 9 primary care centres were randomised into either the intervention group (IG, n=110) or control group (CG, n=112). The IG participated in a PCC add-on through a digital platform and telephone support, both groups received care as usual. Used resources were identified over a 2-year time horizon. Health system costs included directed healthcare costs and costs for drug use, calculated using national statistics and analysed descriptively by cost components. Societal costs accounted for productivity loss using labour market costs, patient co-payments and time spent participating the trial. RESULTS: The IG had lower costs for inpatient care, specialised outpatient care, drug use, and absenteeism due to sick leave. However, polyclinical care was significantly higher in the IG due to a single surgical procedure. The preliminary results of this cost-effectiveness analysis show incremental effects of 0.11 quality-adjusted life years and incremental costs of -95 088 SEK (Swedish crowns). The PCC alternative was both more effective and resulted in lower healthcare costs compared with care as usual. i.e. PCC was dominant. CONCLUSIONS: Based on the preliminary results a remote PCC add-on intervention for people with COPD and / or CHF had lower healthcare costs and higher health-related quality of life than individuals receiving usual care.